Dwight Moxie - 15 Mar 2024 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CLO & GC
Signature
/s/ Dwight Moxie
Issuer symbol
N/A
Transactions as of
15 Mar 2024
Net transactions value
-$58,313
Form type
4
Filing time
19 Mar 2024, 18:44:55 UTC
Previous filing
04 Mar 2024
Next filing
05 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability $17,342 -3,269 -2.2% $5.30 145,940 15 Mar 2024 Direct F1
transaction RVNC Common Stock Sale $40,971 -8,125 -5.6% $5.04 137,815 18 Mar 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the "RSA") for 6,449 shares. The RSA vested in three equal annual installments from March 15, 2021.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units ("PSUs") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F3 The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.